Page last updated: 2024-10-28

haloperidol and Cronkhite-Canada Syndrome

haloperidol has been researched along with Cronkhite-Canada Syndrome in 1 studies

Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279)
haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.

Cronkhite-Canada Syndrome: A nonfamilial polyposis syndrome that is characterized by the presence of diffuse gastrointestinal polyposis, DIARRHEA, and PROTEIN-LOSING ENTEROPATHY. It was first reported by Cronkhite and Canada in 1955.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Peitl, A1
Vucić Peitl, M1
Pavlović, E1
Ljubicić, D1

Other Studies

1 other study available for haloperidol and Cronkhite-Canada Syndrome

ArticleYear
Acute brain syndrome as a consequence of the Cronkhite-Canada syndrome.
    Psychiatria Danubina, 2005, Volume: 17, Issue:1-2

    Topics: Acute Disease; Aged; Dementia; Drug Therapy, Combination; Female; Haloperidol; Humans; Intestinal Po

2005